Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) EBT (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of EBT data on record, last reported at -$364.9 million in Q4 2025.

  • For Q4 2025, EBT fell 86.86% year-over-year to -$364.9 million; the TTM value through Dec 2025 reached -$1.1 billion, down 88.3%, while the annual FY2025 figure was -$1.1 billion, 88.3% down from the prior year.
  • EBT reached -$364.9 million in Q4 2025 per RVMD's latest filing, down from -$305.2 million in the prior quarter.
  • Across five years, EBT topped out at -$37.2 million in Q1 2021 and bottomed at -$364.9 million in Q4 2025.
  • Average EBT over 5 years is -$130.4 million, with a median of -$105.3 million recorded in 2023.
  • Peak YoY movement for EBT: decreased 7.51% in 2022, then tumbled 186.04% in 2023.
  • A 5-year view of EBT shows it stood at -$52.7 million in 2021, then decreased by 7.51% to -$56.6 million in 2022, then crashed by 186.04% to -$162.0 million in 2023, then fell by 20.55% to -$195.3 million in 2024, then tumbled by 86.86% to -$364.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$364.9 million in Q4 2025, -$305.2 million in Q3 2025, and -$247.8 million in Q2 2025.